What is the price-to-earnings ratio of Checkpoint Therapeutics?
The price-earnings ratio of Checkpoint Therapeutics is currently 746.85.
Checkpoint Therapeutics P/S 2024
Checkpoint Therapeutics P/S
746.85
Checkpoint Therapeutics Dividend yield
Ticker
CKPT
ISIN
US1628281073
WKN
A2JAHK
As of May 31, 2024, Checkpoint Therapeutics's P/S ratio stood at 746.85, a 54.3% change from the 484.03 P/S ratio recorded in the previous year.
The Checkpoint Therapeutics P/S history
Checkpoint Therapeutics Aktienanalyse
What does Checkpoint Therapeutics do?
Checkpoint Therapeutics Inc. is a biopharmaceutical company specializing in the development of novel targeted cancer therapies in the field of immuno-oncology. It was founded in 2014 and is headquartered in New York City, USA. Checkpoint Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Checkpoint Therapeutics's P/S Ratio
Checkpoint Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Checkpoint Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Checkpoint Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Checkpoint Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Checkpoint Therapeutics Stock
How has the price-earnings ratio of Checkpoint Therapeutics changed compared to last year?
The price-to-earnings ratio of Checkpoint Therapeutics has increased by 54.3% increased compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Checkpoint Therapeutics high compared to other companies?
Yes, the price-to-earnings ratio of Checkpoint Therapeutics is high compared to other companies.
How does an increase in the price-earnings ratio of Checkpoint Therapeutics affect the company?
An increase in the price-earnings ratio of Checkpoint Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Checkpoint Therapeutics affect the company?
A decrease in the price-earnings ratio of Checkpoint Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Checkpoint Therapeutics?
Some factors that influence the price-earnings ratio of Checkpoint Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Checkpoint Therapeutics pay?
Over the past 12 months, Checkpoint Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Checkpoint Therapeutics is expected to pay a dividend of 0 USD.
What is the dividend yield of Checkpoint Therapeutics?
The current dividend yield of Checkpoint Therapeutics is .
When does Checkpoint Therapeutics pay dividends?
Checkpoint Therapeutics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Checkpoint Therapeutics?
Checkpoint Therapeutics paid dividends every year for the past 0 years.
What is the dividend of Checkpoint Therapeutics?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Checkpoint Therapeutics located?
Checkpoint Therapeutics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Checkpoint Therapeutics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Checkpoint Therapeutics from 5/31/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/31/2024.
When did Checkpoint Therapeutics pay the last dividend?
The last dividend was paid out on 5/31/2024.
What was the dividend of Checkpoint Therapeutics in the year 2023?
In the year 2023, Checkpoint Therapeutics distributed 0 USD as dividends.
In which currency does Checkpoint Therapeutics pay out the dividend?
The dividends of Checkpoint Therapeutics are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Checkpoint Therapeutics
Our stock analysis for Checkpoint Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Checkpoint Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Checkpoint Therapeutics Revenue
- Checkpoint Therapeutics Net Income
- Checkpoint Therapeutics P/E
- Checkpoint Therapeutics P/S
- Checkpoint Therapeutics EBIT
- Checkpoint Therapeutics Dividend
- Checkpoint Therapeutics Stocks
- Checkpoint Therapeutics Market capitalization
- Checkpoint Therapeutics Debt
- Checkpoint Therapeutics Liabilities
- Checkpoint Therapeutics Equity
- Checkpoint Therapeutics AAQS
- Checkpoint Therapeutics Employees
- Checkpoint Therapeutics ROE
- Checkpoint Therapeutics ROA
- Checkpoint Therapeutics ROCE
